Syndax has received FDA approval for Revuforj® (revumenib), marking it as the first menin inhibitor for treating adults and children with relapsed or refractory acute leukemia featuring a KMT2A translocation.

InnoCare reports the initial dosing of a participant in China's Phase III trial of the TYK2 inhibitor ICP-332 for treating atopic dermatitis.

AC Immune Announces Favorable Preliminary Findings from Phase 2 Study of ACI-7104.056 Active Immunotherapy for Early Parkinson’s Disease.

Blenrep demonstrates improved overall survival in the DREAMM-7 phase III trial for relapsed/refractory multiple myeloma.

Levicept Unveils Promising Phase II Results for LEVI-04, a New Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis at ACR Convergence 2024.

Sandoz has obtained approval from the European Commission for Afqlir® (aflibercept), enhancing its prominent biosimilar lineup.

This opinion endorses the approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab for adult patients diagnosed with mild cognitive impairment and mild dementia due to Alzheimer's disease.

Spirovant Sciences has administered the first dose to a patient in the SAAVe Phase 1/2 trial for its experimental aerosol-based genetic treatment for cystic fibrosis.

Kyverna Therapeutics Reveals Patient Data Showcasing KYV-101's Promise for Lupus Nephritis Treatment at ACR Convergence 2024 Symposium.

Soligenix disclosed that it has commenced the enrollment of patients for its Phase 2 trial (protocol number DUS-AUBD-01) investigating SGX945 (dusquetide).

Merck obtains exclusive global rights for LM-299, a clinical investigational bispecific antibody targeting PD-1 and VEGF, from LaNova Medicines Ltd.

Tune Therapeutics Enters Clinical Arena with TUNE-401: A Novel Epigenetic Silencer Targeting Hepatitis B.